The Year in CRISPRs - 14

The Year in CRISPRs * CRISPR-Cpf1 May Outsnip CRISPR-Cas9

The Broad Institute and MIT plan to offer nonexclusive
licenses to enable commercial tool and service providers to
add this enzyme to their CRISPR pipeline and services, further
ensuring availability of this new enzyme to empower research.
These groups plan to offer licenses that best support rapid
and safe development for appropriate and important
therapeutic uses.
"We are committed to making the CRISPR-Cpf1 technology
widely accessible," Zhang explained. "Our goal is to develop
tools that can accelerate research and eventually lead to new
therapeutic applications. We see much more to come, even
beyond Cpf1 and Cas9, with other enzymes that may be
repurposed for further genome editing advances." n

14

| GENengnews.com


http://www.GENengnews.com

The Year in CRISPRs

Table of Contents for the Digital Edition of The Year in CRISPRs

Contents
The Year in CRISPRs - 1
The Year in CRISPRs - 2
The Year in CRISPRs - 3
The Year in CRISPRs - Contents
The Year in CRISPRs - 5
The Year in CRISPRs - 6
The Year in CRISPRs - 7
The Year in CRISPRs - 8
The Year in CRISPRs - 9
The Year in CRISPRs - 10
The Year in CRISPRs - 11
The Year in CRISPRs - 12
The Year in CRISPRs - 13
The Year in CRISPRs - 14
The Year in CRISPRs - 15
The Year in CRISPRs - 16
The Year in CRISPRs - 17
The Year in CRISPRs - 18
The Year in CRISPRs - 19
The Year in CRISPRs - 20
The Year in CRISPRs - 21
https://www.nxtbookmedia.com